NET-2 inhibitors belong to a distinct chemical class characterized by their ability to modulate a specific molecular target known as the norepinephrine transporter subtype 2 (NET-2). This class of compounds primarily acts on the norepinephrine reuptake system, which is responsible for the reabsorption of norepinephrine from the synaptic cleft back into the presynaptic neuron. By inhibiting NET-2, these compounds impede the reuptake process, resulting in an increased concentration of norepinephrine in the synaptic cleft. This modulation of neurotransmitter levels can have various physiological effects due to the involvement of norepinephrine in the central and peripheral nervous systems.
NET-2 inhibitors exhibit a high degree of selectivity for the NET-2 subtype, distinguishing them from inhibitors targeting other norepinephrine transporter subtypes. The precise chemical structure and properties of these inhibitors can vary, allowing for a diverse range of compounds within this class. Researchers have been interested in studying the effects of NET-2 inhibitors on neurotransmission and their impact on neural circuits and systems. Understanding the mechanisms of NET-2 inhibitors may shed light on the intricate processes involved in neurotransmitter regulation and neuronal communication, providing valuable insights into neurobiology and pharmacology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib inhibits NET-2 by competitively binding to the ATP-binding site of the receptor tyrosine kinase, thereby blocking downstream signaling pathways that promote cell growth and angiogenesis. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
Cabozantinib targets NET-2 by inhibiting receptor tyrosine kinases (RTKs), including NET-2, disrupting their signaling cascades involved in cell proliferation and angiogenesis. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Lenvatinib inhibits NET-2 by targeting multiple RTKs, disrupting their downstream signaling pathways responsible for tumor growth and angiogenesis. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
Ponatinib inhibits NET-2 by targeting multiple tyrosine kinases, including those involved in driving tumor growth and angiogenesis, thereby suppressing their signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets NET-2 by inhibiting RTKs and downstream Raf kinases, blocking cell proliferation and angiogenesis pathways. | ||||||